Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM

Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM

Patients with rheumatoid arthritis (RA) may experience residual pain and functional impairment despite good control of disease activity. This study compared improvements in pain and physical function in patients with well-controlled RA after 24 weeks’ treatment with baricitinib, adalimumab or placeb...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Fautrel, B, Kirkham, B, Pope, J, Takeuchi, T, Gaich, C, Quebe, A, Zhu, B, De La Torre, I, De Leonardis, F, Taylor, P
Формат:	Journal article
Хэл сонгох:	English
Хэвлэсэн:	MDPI 2019

Ижил төстэй зүйлс

Improved patient-reported outcomes in patients with rheumatoid arthritis who failed adalimumab or placebo treatment and were rescued with baricitinib
-н: Fautrel, B, зэрэг
Хэвлэсэн: (2017)

Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial
-н: Taylor, P, зэрэг
Хэвлэсэн: (2019)

Baricitinib versus placebo or adalimumab in rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2017)

Rapid and concurrent improvements in patient-reported outcomes of rheumatoid arthritis with baricitinib in RA-BEAM
-н: Strand, V, зэрэг
Хэвлэсэн: (2021)

Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo
-н: Taylor, P, зэрэг
Хэвлэсэн: (2017)

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
-н: Keystone, E, зэрэг
Хэвлэсэн: (2017)

Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC)
-н: Fautrel, B, зэрэг
Хэвлэсэн: (2018)

Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors
-н: Taylor, P, зэрэг
Хэвлэсэн: (2019)

Baricitinib provides greater improvements in patient-reported outcomes across all disease activity levels compared to placebo and adalimumab in rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2021)

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
-н: Tanaka, Y, зэрэг
Хэвлэсэн: (2019)

Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2016)

Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2017)

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: A matching-adjusted indirect comparison
-н: Fautrel, B, зэрэг
Хэвлэсэн: (2020)

Efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate: Summary results from the 52-week phase 3 RA-beam study
-н: Taylor, P, зэрэг
Хэвлэсэн: (2017)

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison
-н: P Emery, зэрэг
Хэвлэсэн: (2020-02-01)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
-н: Schlueter M, зэрэг
Хэвлэсэн: (2019-06-01)

Benefits of pain relief on fatigue, function, and quality of life when joint inflammation is controlled in patients with RA
-н: Van De Laar, M, зэрэг
Хэвлэсэн: (2019)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
-н: Weinblatt, M, зэрэг
Хэвлэсэн: (2017)

Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis
-н: Emery, P, зэрэг
Хэвлэсэн: (2019)

Baricitinib for the treatment of rheumatoid arthritis
-н: Ivan Urits, зэрэг
Хэвлэсэн: (2020-12-01)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
-н: Taylor, P, зэрэг
Хэвлэсэн: (2022)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2019)

Association between baseline haemoglobin levels and radiographic joint damage progression in patients with rheumatoid arthritis treated with baricitinib or standard of care
-н: Moeller, B, зэрэг
Хэвлэсэн: (2019)

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
-н: Taylor, PC, зэрэг
Хэвлэсэн: (2023)

Efficacy and safety of switching from adalimumab to baricitinib: long-term data from phase 3 extension study in patients with rheumatoid arthritis
-н: Weinblatt, M, зэрэг
Хэвлэсэн: (2018)

Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study
-н: Emery, P, зэрэг
Хэвлэсэн: (2017)

Cutaneous eruption after commencing baricitinib for rheumatoid arthritis
-н: Rosemary Akinbisehin, зэрэг
Хэвлэсэн: (2024-06-01)

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
-н: Rieke Alten, зэрэг
Хэвлэсэн: (2022-10-01)

Baricitinib exposure during pregnancy in rheumatoid arthritis
-н: Giulia Costanzo, зэрэг
Хэвлэсэн: (2020-01-01)

Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study.
-н: Ignacio Ortea, зэрэг
Хэвлэсэн: (2016-01-01)

Lack of clinical disease activity response at 4 weeks of baricitinib treatment as a negative predictor of remission at weeks 12 and 24 in patients with rheumatoid arthritis: results from two phase 3 studies (RA-BEAM and RA-BEGIN)
-н: Tanaka, Y, зэрэг
Хэвлэсэн: (2021)

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
-н: Yue Yang, зэрэг
Хэвлэсэн: (2020-09-01)

Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA
-н: Vibeke Strand, зэрэг
Хэвлэсэн: (2024-08-01)

Baricitinib: Early vs. delayed start in patients with rheumatoid arthritis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2018)

Cost per number needed to treat and treatment cost of baricitinib versus adalimumab on rheumatoid arthritis treatment in the brazilian private healthcare system
-н: Bruno Corona Prandi, зэрэг
Хэвлэсэн: (2023-02-01)

Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis
-н: Taylor, P, зэрэг
Хэвлэсэн: (2022)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
-н: Gerd Burmester, зэрэг
Хэвлэсэн: (2020-02-01)

ADALIMUMAB: NEW OPPORTUNITIES OF RHEUMATOID ARTHRITIS TREATMENT
-н: E.I. Alexeeva, зэрэг
Хэвлэсэн: (2009-05-01)

ADALIMUMAB: NEW OPPORTUNITIES OF RHEUMATOID ARTHRITIS TREATMENT
-н: E.I. Alexeeva, зэрэг
Хэвлэсэн: (2009-01-01)

Adalimumab in the treatment of early rheumatoid arthritis
-н: Y A Sigidin, зэрэг
Хэвлэсэн: (2008-04-01)